Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06597019
PHASE3

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

Sponsor: Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 6 to \<12 years) with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDLC).

Official title: Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children (6 to Less Than 12 Years) With Heterozygous Familial Hypercholesterolemia and Elevated LDL- Cholesterol

Key Details

Gender

All

Age Range

6 Years - 11 Years

Study Type

INTERVENTIONAL

Enrollment

51

Start Date

2024-12-09

Completion Date

2029-04-15

Last Updated

2025-11-21

Healthy Volunteers

No

Interventions

DRUG

Inclisiran

Inclisiran (inclisiran sodium 300 mg subcutaneous (s.c.) for participants with body weight ≥23 kg and inclisiran sodium 180 mg s.c. for participants with body weight \<23 kg. The dose level is based on the participant's body weight on Day 1 (for Part 1) and Day 360 (for Part 2), respectively.

DRUG

Placebo

Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)

Locations (66)

UC San Francisco Medical Center

San Francisco, California, United States

UC San Francisco Medical Center

San Francisco, California, United States

Children's National Hospital

Washington D.C., District of Columbia, United States

Childrens National Hospital

Washington D.C., District of Columbia, United States

Excel Medical Clinical Trials LLC

Boca Raton, Florida, United States

Icahn School of Med at Mt Sinai

New York, New York, United States

Primary Childrens Medical Center

Salt Lake City, Utah, United States

Primary Childrens Medical Center

Salt Lake City, Utah, United States

Virginia Commonwealth University

Richmond, Virginia, United States

West Virginia Childrens Hospital

Morgantown, West Virginia, United States

West Virginia Childrens Hospital

Morgantown, West Virginia, United States

Novartis Investigative Site

Buenos Aires, Argentina

Novartis Investigative Site

CABA, Argentina

Novartis Investigative Site

Salzburg, Austria

Novartis Investigative Site

Vienna, Austria

Novartis Investigative Site

Brussels, Belgium

Novartis Investigative Site

Leuven, Belgium

Novartis Investigative Site

Fortaleza, Ceará, Brazil

Novartis Investigative Site

Rio de Janeiro, Rio de Janeiro, Brazil

Novartis Investigative Site

Porto Alegre, Rio Grande do Sul, Brazil

Novartis Investigative Site

São Paulo, São Paulo, Brazil

Novartis Investigative Site

Beijing, Beijing Municipality, China

Novartis Investigative Site

Shanghai, China

Novartis Investigative Site

Prague, Czechia

Novartis Investigative Site

Prague, Czechia

Novartis Investigative Site

Marseille, France

Novartis Investigative Site

Nantes, France

Novartis Investigative Site

Paris, France

Novartis Investigative Site

Freiburg im Breisgau, Baden-Wurttemberg, Germany

Novartis Investigative Site

Frankfurt am Main, Hesse, Germany

Novartis Investigative Site

Hanover, Germany

Novartis Investigative Site

Athens, Greece

Novartis Investigative Site

Ioannina, Greece

Novartis Investigative Site

Hong Kong, Hong Kong

Novartis Investigative Site

Budapest, Hungary

Novartis Investigative Site

Jerusalem, Israel

Novartis Investigative Site

Ramat Gan, Israel

Novartis Investigative Site

Milan, MI, Italy

Novartis Investigative Site

Roma, RM, Italy

Novartis Investigative Site

Torino, TO, Italy

Novartis Investigative Site

Verona, VR, Italy

Novartis Investigative Site

Kuala Lumpur, Kuala Lumpur, Malaysia

Novartis Investigative Site

Amsterdam, North Holland, Netherlands

Novartis Investigative Site

Bialystok, Poland

Novartis Investigative Site

Gdansk, Poland

Novartis Investigative Site

Lodz, Łódź Voivodeship, Poland

Novartis Investigative Site

Coimbra, Portugal

Novartis Investigative Site

Lisbon, Portugal

Novartis Investigative Site

Porto, Portugal

Novartis Investigative Site

Porto, Portugal

Novartis Investigative Site

Bloemfontein, Free State, South Africa

Novartis Investigative Site

Elche, Alicante, Spain

Novartis Investigative Site

Cadiz, Andalusia, Spain

Novartis Investigative Site

Esplugues, Barcelona, Spain

Novartis Investigative Site

Badalona, Catalonia, Spain

Novartis Investigative Site

Pamplona, Navarre, Spain

Novartis Investigative Site

Barcelona, Spain

Novartis Investigative Site

Málaga, Spain

Novartis Investigative Site

Seville, Spain

Novartis Investigative Site

Taipei, Taiwan

Novartis Investigative Site

Taipei, Taiwan

Novartis Investigative Site

Adana, Saricam, Turkey (Türkiye)

Novartis Investigative Site

Ankara, Yenimahalle, Turkey (Türkiye)

Novartis Investigative Site

Izmir, Turkey (Türkiye)

Novartis Investigative Site

West Midlands, Birmingham, United Kingdom

Novartis Investigative Site

London, United Kingdom